Jose Manuel Valdivielso Revilla
Grau: Doctor/a
973 702 952
valdivielso(ELIMINAR)@irblleida.cat
ResearcherID: http://www.researcherid.com/rid/B-5673-2009
Publicacions
-
Bermudez-Lopez M; Perpiñan H; Amigo N; Castro E; Alonso N; Mauricio D; Fernandez E; Valdivielso JM
Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients.
CLINICAL KIDNEY JOURNAL 14 2591-2599. .
-
Bermúdez-López M; Martínez-Alonso M; Castro-Boqué E; Betriu À; Cambray S; Farràs C; Barbé F; Pamplona R; Lecube A; Mauricio D; Purroy F; Valdivielso JM; Fernández E; ILERVAS project collaborators
Subclinical atheromatosis localization and burden in a low-to-moderate cardiovascular risk population: the ILERVAS study.
REVISTA ESPANOLA DE CARDIOLOGIA 74 1042-1053. .
-
Solache-Berrocal G; Rolle-Sóñora V; Martín-Fernández N; Cambray S; Valdivielso JM; Rodríguez I
CYP24A1 and KL polymorphisms are associated with the extent of vascular calcification but do not improve prediction of cardiovascular events.
NEPHROLOGY DIALYSIS TRANSPLANTATION 36 2076-2083. .
-
Valdivielso JM; Balafa O; Ekart R; Ferro CJ; Mallamaci F; Mark PB; Rossignol P; Sarafidis P; Del Vecchio L; Ortiz A
Correction to: Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies.
DRUGS 81 1819-1819. .
-
Castelblanco E; Sarrias MR; Betriu À; Soldevila B; Barranco-Altirriba M; Franch-Nadal J; Valdivielso JM; Bermudez-Lopez M; Groop PH; Fernández E; Alonso N; Mauricio D
Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease.
Aging-US 13 22690-22709. .
-
Alonso-Perez E; Forné C; Soro M; Valls M; Manganelli AG; Valdivielso JM
Health Care Costs in Patients with and without Secondary Hyperparathyroidism in Spain.
Advances in Therapy 38 5333-5344. .
-
Mota-Zamorano S; Robles NR; González LM; Valdivielso JM; Lopez-Gomez J; Cancho B; García-Pino G; Gervasini G
Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy.
Journal of Clinical Medicine 10 -. .
-
Valdivielso, JM; Balafa, O; Ekart, R; Ferro, CJ; Mallamaci, F; Mark, PB; Rossignol, P; Sarafidis, P; del Vecchio, L; Ortiz, A
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
DRUGS 81 1467-1489. .
-
González LM; Robles NR; Mota-Zamorano S; Valdivielso JM; López-Gómez J; Gervasini G
Genetic Variants in PGE2 Receptors Modulate the Risk of Nephrosclerosis and Clinical Outcomes in These Patients.
Journal of Personalized Medicine 11 -. .
-
Vila MDM; Remeseiro B; Igual L; Elosua R; Ramos R; Valdivielso JM; Martí-Lluch R; Marrugat J; Grau M
Do individuals with autoimmune disease have increased risk of subclinical carotid atherosclerosis and stiffness?
HYPERTENSION RESEARCH 44 978-987. .
-
Del Mar Vila M; Remeseiro B; Igual L; Elosua R; Ramos R; Valdivielso JM; Martí-Lluch R; Marrugat J; Grau M
Correction: Do individuals with autoimmune disease have increased risk of subclinical carotid atherosclerosis and stiffness?
HYPERTENSION RESEARCH 44 1046-1046. .
-
Saumoy, M; Di Yacovo, S; Perez, S; Sanchez-Quesada, JL; Valdivielso, JM; Subirana, I; Imaz, A; Tiraboschi, JM; Garcia, B; Ordonez-LLanos, J; Benitez, S; Podzamczer, D; Grau, M
Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equations
HIV MEDICINE 22 581-591. .
Projectes
- Estancias de personal docente y/o investigador senior en centros extranjeros 2022
- El primer Estudio de asociación de genoma completo (GWAS) con enfermedad coronaria poblacional a 10 años en más de 100.000 participantes para personalizar la prevención cardiovascular en España
- Influence of SARS-COV-2 infection in atherosclerosis development. “El BUS DE LA SALUT” study
- SPAIN CKD CAUSE (SPACKDC)
- INVESTIGO 2022: Grup de recerca translacional vascular i renal
- Papel de PTEN en la reabsorcion tubular renal de proteinas. Implicaciones en nefropatias proteinuricas
- Preservació la membrana peritoneal abordant noves vies per inhibir la transició mesotelio-mesenquimal.
- Acciones de Dinamización "Europa Investigación 2020"
- Contratos Sara Borrell
- Papel de la vía PI3K/AKT/mTOR en la regulación de las alteraciones del metabolismo mineral en la enfermedad renal crónica. Implicaciones en la regulación de la síntesis de FGF23.
- Ajuts destinats a contractar personal investigador novell (FI)
- Ayudas Juan de la Cierva-formación